NOVATO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK:MNTM) is pleased to announce that Dr. Jim Stolzenbach has been appointed as a scientific advisor to Mount Tam, bringing his expertise in drug development to support the advancement of our novel rapamycin analogs to address serious unmet need across a range of autoimmune and rare diseases.
According to Dr. Richard Marshak, Mount Tam CEO, “Dr. Stolzenbach is a critical addition to our team of advisors. Jim’s leadership experience and track record of success in the cardiovascular, renal and autoimmune spaces will help Mount Tam to optimize our clinical development programs now and into the future.”
Jim Stolzenbach Ph.D. has extensive research and development experience in the pharmaceutical industry where currently he is President of Jim Stolzenbach Consulting, LLC. Jim is the former Vice President for Abbvie Renal and Immunology Therapeutic Development. Previously, he held several senior leadership roles with Monsanto and Pharmacia including Vice President for Cardiovascular and Metabolic Product Development. Jim has led global projects for both small molecule and biologic programs ranging from proof of concept trials to large Phase 3 trials designed for regulatory approval. During the course of his career he has co-authored over 30 publications in refereed journals with numerous abstracts for presentation. Jim has a Bachelor’s degree in Science from the University of Connecticut, a Master’s degree from the University of Georgia and obtained his Ph.D. at Oregon State University.
“I am extremely excited about the opportunity to work with the quality team at Mount Tam and helping them bring these exciting new compounds into clinical development,” says Dr. Stolzenbach.
About Mount Tam Biotechnologies, Inc.
Mount Tam Biotechnologies, Inc. was established to develop, optimize and bring to market leading medical compounds to better the health and well being of millions of people who have been affected by autoimmune diseases. The organization's most advanced product focuses on the treatment of systemic lupus erythematosus (SLE).
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets, which are focused on autoimmune diseases, are highly target-specific polyketides--a class of compounds with an extremely successful track record with the FDA drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.
Mount Tam intends to apply its first and most advanced asset, TAM-01, to the Investigational New Drug (IND) application phase of the FDA. It has already completed non-GLP pre-clinical development. The primary focus is to develop TAM-01 for the treatment of systemic lupus erythematosus (SLE). Mount Tam will use the R&D conducted on TAM-01 as the core science for additional assets, including its second product known as TAM-02, which is currently focused on multiple sclerosis (MS).
For more information visit www.MountTamBiotech.com
The information disclosed in this press release is made as of the date hereof and reflects Mount Tam’s most current assessment of its historical position and financial performance. Actual results may differ from those contained herein due to factors outside of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.
These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as "scheduled (future sense)" "intend(s)", "plan(s)" "expect(s)", "believe(s)", "will", "estimate(s)", "anticipate(s)", "expect(s)", "may", "would", "could" or "should" or, in each case, the negative thereof, other variations thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of any such application. Although Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking statements for subsequent events.
Company Contact: Jim Stapleton Chief Financial Officer email@example.com Phone: 425-214-4079
Source:Mount Tam Biotechnologies, Inc.